Medtronic (NYSE:MDT) Earns “Buy” Rating from TD Cowen

Medtronic (NYSE:MDT)‘s stock had its “buy” rating reissued by investment analysts at TD Cowen in a research note issued on Thursday,Benzinga reports. They currently have a $119.00 price target on the medical technology company’s stock. TD Cowen’s price objective suggests a potential upside of 44.91% from the stock’s current price.

Other equities research analysts have also issued research reports about the company. Stifel Nicolaus set a $80.00 price target on Medtronic in a research report on Wednesday. JPMorgan Chase & Co. decreased their price target on shares of Medtronic from $100.00 to $86.00 and set a “neutral” rating for the company in a research note on Thursday. Wells Fargo & Company dropped their price target on Medtronic from $114.00 to $102.00 and set an “overweight” rating on the stock in a research note on Thursday. Leerink Partners lowered their target price on Medtronic from $117.00 to $104.00 and set an “outperform” rating on the stock in a research report on Thursday. Finally, Barclays lifted their price target on shares of Medtronic from $118.00 to $120.00 and gave the company an “overweight” rating in a research report on Wednesday, April 1st. Sixteen research analysts have rated the stock with a Buy rating and eleven have assigned a Hold rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $99.35.

Medtronic Price Performance

NYSE:MDT traded up $4.17 during mid-day trading on Thursday, reaching $82.12. The stock had a trading volume of 4,221,701 shares, compared to its average volume of 9,080,472. Medtronic has a 12 month low of $73.31 and a 12 month high of $106.33. The stock has a market capitalization of $105.43 billion, a PE ratio of 22.85, a P/E/G ratio of 1.76 and a beta of 0.58. The company has a debt-to-equity ratio of 0.57, a current ratio of 2.54 and a quick ratio of 1.87. The stock has a 50-day simple moving average of $81.67 and a two-hundred day simple moving average of $92.21.

Medtronic (NYSE:MDT) last released its earnings results on Wednesday, June 3rd. The medical technology company reported $1.55 earnings per share for the quarter, topping the consensus estimate of $1.54 by $0.01. The firm had revenue of $9.81 billion during the quarter, compared to analysts’ expectations of $9.62 billion. Medtronic had a return on equity of 14.82% and a net margin of 13.00%.The company’s quarterly revenue was up 9.9% on a year-over-year basis. During the same period in the prior year, the company earned $1.62 earnings per share. Medtronic has set its FY 2027 guidance at 5.900-6.000 EPS. On average, equities analysts anticipate that Medtronic will post 5.54 earnings per share for the current year.

Institutional Investors Weigh In On Medtronic

Large investors have recently modified their holdings of the stock. Norges Bank bought a new position in Medtronic during the fourth quarter valued at approximately $1,653,485,000. WCM Investment Management LLC bought a new stake in shares of Medtronic in the 1st quarter worth approximately $965,922,000. Capital Research Global Investors boosted its stake in shares of Medtronic by 12.6% in the 4th quarter. Capital Research Global Investors now owns 34,573,163 shares of the medical technology company’s stock valued at $3,321,101,000 after purchasing an additional 3,880,174 shares in the last quarter. Barclays PLC boosted its stake in shares of Medtronic by 104.6% in the 3rd quarter. Barclays PLC now owns 6,831,203 shares of the medical technology company’s stock valued at $650,604,000 after purchasing an additional 3,492,192 shares in the last quarter. Finally, Schroder Investment Management Group grew its holdings in shares of Medtronic by 78.3% during the 3rd quarter. Schroder Investment Management Group now owns 7,529,849 shares of the medical technology company’s stock valued at $717,143,000 after purchasing an additional 3,307,211 shares during the last quarter. Hedge funds and other institutional investors own 82.06% of the company’s stock.

Key Medtronic News

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Medtronic reported fiscal Q4 revenue of $9.81 billion and adjusted EPS of $1.55, both ahead of estimates, which reinforced the recent stock move higher.
• Positive Sentiment: Cardiac Ablation Solutions revenue surged 78% globally, helping offset margin pressure and signaling strong demand in a key growth franchise.
• Positive Sentiment: Management lifted its quarterly dividend to $0.72 per share and kept FY2027 growth targets intact, supporting the case for continued operational momentum.
• Positive Sentiment: Medtronic also announced new strategic investments and FDA-related submissions to expand its Hugo robotic-assisted surgery platform, which could add future growth opportunities. Medtronic submits 510(k) filings to expand Hugo robotic-assisted surgery system
• Neutral Sentiment: Several analysts lowered price targets this morning, but most kept constructive ratings such as overweight, outperform, or buy, suggesting valuation concerns rather than a changed bullish thesis.
• Neutral Sentiment: Wells Fargo cut its target to $102 from $114 and Leerink cut to $104 from $117, while Robert W. Baird reduced its target to $85 and kept a neutral rating.
• Negative Sentiment: Medtronic’s FY2027 EPS guidance of $5.90 to $6.00 came in below the consensus estimate, which may temper some of the post-earnings enthusiasm.
• Negative Sentiment: Margins remain a focus as the company flagged tariff and cost headwinds, which could pressure profitability even as sales improve.

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).